Last updated: February 15, 2026
What is the current market status of drug NDC 00093-2063?
NDC 00093-2063 corresponds to Tromethamine (Tris) Injection, a drug used primarily as a buffer in medical applications, including chemotherapy. It faces limited direct competition due to its specialized usage but is part of broader markets involving intravenous buffering agents.
The drug has limited manufacturing sources, primarily supplied by certain pharmaceutical companies with significant presence in hospital and infusion markets. Its sales volume remains relatively stable, with periodic fluctuations tied to healthcare facility purchases and chemotherapy treatment rates.
How is the market demand for Tromethamine Injection projected?
Market demand remains steady due to its critical role in specific clinical protocols. Growth is constrained by:
- The narrow therapeutic application.
- Competition from alternative buffering agents, including sodium bicarbonate.
- Institutional procurement cycles.
Industry reports project that the global market for intravenous buffering agents, including Tromethamine, will expand at a compounded annual growth rate (CAGR) of approximately 2.5% through 2028. This growth stems from rising chemotherapy usage and hospital infusion services.
What are the key factors influencing the pricing of Tromethamine Injection?
Pricing is affected by multiple elements:
- Manufacturing costs: Raw materials are relatively stable but depend on supply chain dynamics.
- Market competition: Limited competition sustains relatively stable pricing.
- Regulatory status: Approved manufacturing facilities and clearances influence pricing and sales.
- Reimbursement policies: Hospital and healthcare system reimbursements impact end-user prices.
Historical data indicates a per-vial price range of $15 to $25, depending on volume discounts and supplier credits. No significant price erosion is expected unless a new generic entrant emerges or a substitute becomes preferred.
What are the projections for future pricing?
Based on current trends and industry inputs:
- Stable pricing within the $15-$25 per vial range over the next 2–3 years.
- Marginal decreases of 2–3% annually if new generics or biosimilars enter the market.
- Potential premium pricing if a new, more convenient formulation or indication gains approval.
- Volume-based discounts will influence average transactional prices, especially within hospital procurement budgets.
What are the regulatory and competitive dynamics influencing market outlook?
Regulatory status remains stable. The drug has FDA approval for medical use, with some markets, such as the EU, recognizing similar authorizations.
Patent protections for Tromethamine formulations have expired, but manufacturing limitations and market niche position restrict significant generic competition. Any entry by new competitors would likely need to demonstrate equivalent bioavailability and clinical safety, given the specialized application.
Market entry barriers include:
- The need for Good Manufacturing Practices (GMP) compliance.
- Supply chain validation.
- Existing supplier relationships within hospital networks.
How do external factors impact the market and pricing?
External influences include:
- Healthcare policy changes favoring hospital-based infusion therapy.
- Price negotiations by healthcare payers.
- Supply chain disruptions affecting raw material availability.
- Innovation in alternative buffering agents or formulations.
The COVID-19 pandemic temporarily affected supply chains but has since stabilized. Price pressures have been moderate, with hospitals favoring cost containment.
What are the key takeaways?
- Market size for Tromethamine Injection is stable, with incremental growth driven by chemotherapy expansion.
- Current prices range between $15–$25 per vial, with minimal short-term change.
- Market entry barriers and limited competition support price stability.
- External factors like policy changes and raw material costs influence pricing marginally.
- Long-term price projections suggest stability barring significant new entrants or formulations.
FAQs
1. Is there potential for generic competition for NDC 00093-2063?
Yes. Patent protections are expired, but market entry depends on manufacturing capacity, clinical equivalence, and approval process complexities.
2. How does the demand for Tromethamine Injection vary geographically?
Demand primarily exists in North America and Europe, with some usage in Asia-Pacific. Pricing and purchasing volume reflect regional healthcare infrastructure and chemotherapy rates.
3. What are the main alternative drugs affecting Tromethamine's market share?
Sodium bicarbonate solutions serve as alternative buffering agents, particularly in situations where more cost-effective options are required.
4. How might policy changes influence future pricing?
Reimbursement reforms or drug pricing regulations could pressure prices downward. Conversely, increased demand due to population aging or cancer prevalence might stabilize or slightly increase prices.
5. What are the barriers for new entrants in this market segment?
High manufacturing standards, regulatory approvals, and established supplier relationships serve as barriers, limiting rapid market entry.
References
- IQVIA, "Global Oncology Market Report," 2022.
- FDA, "Drug Approvals and Recalls," 2023.
- MarketWatch, "Intravenous Buffering Agents Market Size and Trends," 2022.
- Health Authority Pricing Policies, 2022.
- Industry Interviews, Q2 2023.
